Therapy with of RCHOP-14 Versus RCHOP-21 for People With Aggressive or Advanced Stage Indolent B-Cell Non-Hodgkins Lymphoma: A Systematic Review and Meta-Analysis

Yue He  
The 1st Affiliated Hospital of Nanchang University

Wenqiang Tao  
First Affiliated Hospital of Nanchang University

Dexiang Ji  
First Affiliated Hospital of Nanchang University

Wei Lu  
First Affiliated Hospital of Nanchang University

Yu Xiong  
The 1st Affiliated Hospital of Nanchang University

Guoan chen (chenguoan2020@yeah.net)  
The 1st Affiliated Hospital of Nanchang University

Keywords: aggressive, indolent, B-cell lymphoma, RCHOP, a systematic review, meta-analysis

DOI: https://doi.org/10.21203/rs.3.rs-103091/v1

License: ☛  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** With the advent of rituximab, RCHOP is considered the appropriate chemotherapy for aggressive or advanced stage indolent B-cell Non-Hodgkin's Lymphoma (NHL). RCHOP-14 seems to achieve better outcomes than RCHOP-21 in aggressive or advanced stage indolent B-cell NHL patients in recent years.

**Methods:** To verify the befitting chemotherapy regimens for B-cell NHL patients, we searched the electronic databases for relevant English-language literature published through January 2020. The primary outcomes were complete response (CR), progression-free survival (PFS), overall survival (OS), and Adverse events (AEs). Six eligible Phase II and III clinical randomized controlled trials (RCTs) and two high-quality observational comparative studies (OCSs) were extracted, and 5565 B-cell NHL patients involved in evaluable.

**Results:** The analysis demonstrated no significant difference for CR rate (OR = 0.98, 95%CI 0.77-1.24, P = 0.85) between RCHOP-14 and RCHOP-21. Compared with RCHOP-21, the merged hazard ratio (HR) for PFS and OS was, respectively, 0.94 (95% CI: 0.84-1.06, P = 0.32) and 0.91 (95% CI: 0.83-1.01, P = 0.08) after treatment with RCHOP-14. A subgroup analysis based on the international prognostic index (IPI) score showed that both chemotherapy regimens were applicable in B-cell NHL patients with different prognosis. The frequency of toxic side-effects was similar between schemes.

**Conclusions:** Therefore, the data presented suggest that the efficacy and safety of both regimens are comparable and that R-CHOP14 remains a viable plan in B-cell NHL patients who prefer a shorter therapy course.

Background

Aggressive and indolent lymphomas are two subtypes of B-cell-derived NHL, and they have different chemotherapy regimens depending on the prognosis. Aggressive NHL is a highly aggressive malignancy with a poor outcome, which is a greatly chemo-sensitive tumor and is highly curable (1). Advanced stage indolent NHL is often incurable and can easily be converted to aggressive lymphoma, but it can be alleviated with a regimen of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP) (2, 3). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive lymphoma, which is a disease of biologically, histopathologically, and clinically heterogeneous entity (4). The median survival of NHL patients without prompt treatment was less than one year, on account of its aggressive nature (5, 6). For a long time, the first-line chemotherapy treatment for DLBCL is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which is more reasonable to choose CHOP-21 that is every 3 weeks in combination. Some RCTs were enquired about the survival analysis of dose-intensified regimens, and then showing that the two-week cycle of chemotherapy (CHOP-14) is superordinate than the CHOP-21 (7, 8).

There is a human/murine chimeric anti-CD20 monoclonal antibody called rituximab, which has a credible efficacy. It has a well-defined and adequately safe for patients with various lymphoid malignancies that CD20-expressing, such as aggressive and indolent forms of B-cell NHL (9). Follicular lymphoma (FL) is a neoplasm comprising germinal center B cells, is a subgroup of indolent lymphomas, and the rituximab-CHOP is the standard option for advanced-stage FL patients (10). NHL (PMBL) is a unique subtype of DLBCL, which originates from thymic B-cells in the mediastinum. The RCHOP regimen with or without consolidative radiotherapy (RT) is the first-line management of PMBL (11). For all of these diseases, which include DLBL, FL, mantle cell lymphoma (ML), and chronic lymphocytic leukemia, it can be proved that rituximab-based treatment not only extends the time of progression-free survival but also prolongs the overall survival time (12). Therefore, it is meaningful to discuss the choice of RCHOP-14 vs 21 chemotherapy regimen based on rituximab for aggressive or advanced stage indolent B-cell NHL.

We implement trails from RCTs and OCSs to estimate the efficacy and toxicity of a chemotherapy regimen as RCHOP-14 compared to RCHOP-21 for patients with B-cell NHL, the results as an on CR, PFS, OS and toxic.

Methods

**Search strategy**

Firstly, we search to conduct a systematic and comprehensive search from original to January 2020 throughout databases, including PubMed, Web of Science, Embase, Cochrane Library, ClinicalTrials.gov. The predefined keywords with Boolean operators were used for the search: (“RCHOP-14 AND RCHOP-21” OR “dose-dense”) AND “lymphoma”. The electronic search was complemented by a manual search for additional articles in reference lists and previous reviews, rendering certain a full-scale investigation.

**Selection criteria**
We enrolled trials must meeting the below inclusion criteria: (1) studies based on RCTs and high-quality OCSs; (2) participants were newly diagnosed aggressive lymphoma at clinical stage I to IV or untreated advanced-stage indolent B-cell NHL; (3) comparative analysis of RCHOP-14 and RCHOP-21 for treating B-cell NHL; (4) follow-up duration longer than 36 months; (5) CR/PFS or OS was existence outcome in the articles. The containing of duplicated data that might lead to an overestimation of intervention effects was cautious. Review articles, conference abstracts, nonhuman studies, case reports, abstracts, and unpublished data were excluded from consideration. Moreover, studies had no extractable data that were also excluded. A senior referee was consulted if divergence regarding which studies to include.

Data extraction and quality assessment

Relevant Data were extracted from included articles by two authors independently. The following data were extracted: the first author, published year, location, disease, stage, median age, median follow-up, number of patients with IPI at different levels, sample size, number of cycles, and clinical outcomes, including CR, PFS, OS and toxicity. We assessed the quality of RCTs using the Cochrane Collaboration’s risk of bias tool Rev Man 5.3. The quality of selected studies will be appraised with methodological domains as follows: risks of selection, performance, detection, attrition, and reporting biases. For the included study, types of bias are divided into 3 levels: low, unclear, high. The Newcastle-Ottawa-Scale (NOS) uses three categories: the selection of study groups, comparability, and outcome assessment, respectively, to evaluate the risk of bias of OCSs.

Statistical analysis

A meta-analysis of variables with three or more studies was performed when the outcome was reported. Statistical heterogeneity among individual studies was calculated by the P and I² test, and heterogeneity will be considered substantive if I² > 50%.(13). The fixed-effect model and the random-effects model were utilized for consistent and heterogeneous studies, respectively, in accordance with the previously published guidelines for statistical reporting and a systematic review manual on Cochrane interventions. PFS and OS, as the dichotomous data, were reported with hazard ratios (HRs) and 95%CIs. HR is calculated by the inverse of variance to weigh the size of the individual effect. CR rate was calculated by odds ratio (OR) with the random-effects model (M-H methods), and adverse events to analyze using the Risk Ratio (RR) were calculated either the same model. Then, the forest map for meta-analysis was drawn. If possible, sensibility analysis is conducted to investigate the origins of heterogeneity. Funnel plots were performed to confirm attest to the presence of publication bias. All statistical analyses were conducted in Review Manager 5.3.

Results

Description of studies

A total of 403 potentially relevant studies were ascertained after the initial search (Figure 1). Of these, 31 articles from PubMed, 59 from Embase, 173 from Web of Science, 134 from Cochrane Library and 6 from clinicaltrials.gov. Then, 181 papers not relevant articles and 142 duplicated articles were expurgated by carefully reviewing the titles and abstracts. 66 pieces of literature were deleted by reason that these trials were conference reports, non-original data or data scarcity, review or meta-analysis, not RCHOP-14 VS RCHOP-21 and relative results. Finally, 6 RCTs (Cunningham et al., 2013, Delarue et al., 2013, Payandeh et al., 2016, Watanabe et al., 2018, Li et al., 2019, Gleeson et al. 2016) and 2 OCSs (Wästerlid et al., 2017, Knauf et al., 2019) met all inclusion criteria entered in this meta-analysis (14-21).

Type of patients

In total, five studies included 5565 patients with B-cell NHL, whom 2892 underwent RCHOP-14, and 2673 underwent RCHOP-21 only. The experimental characteristics of each RCT are summarized in Table 1. Most of the enrolled trials in different countries, four of which are included in Europe, four trails accounting for studies were in Asian. We collected patients with clinical stage I-IV aggressive lymphoma and untreated III-IVV stage indolent B-cell NHL, who were older than 18 years. G-CSF (Granulocyte Colony Factor) was applied to both the RCHOP-14 group and the RCHOP-21 group to shorten CHOP. -Stimulating Moreover, the sample sizes for individual studies varied widely from 50 to 2106 despite were multi-center clinical trials.

Quality assessment

Six RCTs were assessed as low risk in the light of a suitable option (Figure 2A and 2B). However, four of RCTs have a high risk of selection bias as Allocation concealment (14, 16, 18, 21). All funnel plots of PFS and OS were symmetrical, indicating no publication bias (Figure 2C and 2D). The selection of high-quality OCSs was based on a validated tool. Two OCSs were evaluated by NOS (Table 2), and the results suggested that both of them were high-quality literature.

Efficacy
Complete response rate data were available from 8 studies (14-21): incorporating 2657 patients from the RCHOP-14 therapeutic regimen and 2415 patients from the RCHOP-21 regimen. As shown in Figure 3, we find that significant heterogeneity within these two regimes ($\chi^2=17.69, P=0.007, I^2=66\%$): then the random-effects model was used. CR rate not meliorated with RCHOP-14 regimens in patients (OR= 0.96, 95% CI 0.76–1.23, P= 0.76). The results of the RCTs and OCSs were consistent, so we calculated the data together and displayed it on a graph.

**Survival**

The PFS and OS of RCHOP-14 versus RCHOP-21 as the main long-term clinical outcome evaluation with B-cell lymphoma. Figure 4 and 5 suggest that no significant between-trial heterogeneity was observed between PFS and OS, then, we choose the fixed-effect model. The results of the OCSs were consistent with the RCTs, so we presented these data in a single graph and stratified the clinical outcomes of patients with different prognoses based on IPI. For the comparison, PFS was curtailed in RCHOP-14, but it showed no significant difference ($HR = 0.94, 95\% CI 0.84–1.06, P = 0.32$). Results were not altered after differentiating patients with different IPI scores: Figure 4i; in other words, the two regimens of chemotherapy are equivalent for patients with aggressive or indolent lymphoma. As shown in Figure 5, regarding OS, there was a tendency that RCHOP-14 was superior to RCHOP-21 (HR=0.91, 95% CI 0.83–1.01, P= 0.08). However, there was still no statistical difference among the trials. After stratification according to the IPI score, the OS of patients with different prognosis was in agreement with the outcome indicators of all patients.

**Treatment-related toxicity**

AEs with both RCHOP-14 and RCHOP-21 treatment protocol were reviewed in all RCTs, including both hematological and non-hematological toxicities. Table 3 summarizes the grade ≥ 3 adverse events. we have used RR (Risk Ratio) values to compare the adverse events of the five studies in the supplementary picture, the toxicity of RCHOP-14 regimen and RCHOP-21 regimen has no significant high risk (RR=0.98, 95% CI 0.83–1.15, P=0.73). $I^2 = 85\%$ suggested greater heterogeneity among the trials, which was statistically significant. The subgroup analysis results on hematological AEs that the incidences of thrombocytopenia (RR= 0.87, 95% CI 0.60–1.25, P = 0.44) were higher in the RCHOP-14 arm[9, 10, 12-14], although there is no statistical significance. One of subgroup analysis were observed with patients who received RCHOP-21, which has a higher trend to have Anemia when removing to Watanabe et.al. (RR = 1.15, 95% CI 0.88–1.50, P= 0.29) (14, 17, 18). The subgroup analysis on non-hematological AEs indicates that Patients treated with RCHOP-21 had a higher risk of neurological-related, which were not statistically significant (RR= 1.41, 95% CI 0.85–2.33, P= 0.18).

**Discussion**

In clinical, RCHOP-14 and RCHOP-21 are the two different international standards, respectively, which were used for the treatment of B-cell lymphoma. This manuscript implies that the CR rate, PFS, and OS were higher in patients who assigned to RCHOP-14 therapy, but its outcomes did not differ significantly. This indicates that the CR rate, PFS, and OS in these patients may be unable to be improved through the way RCHOP-14. Whether the addition of radiotherapy can change this outcome requires more RCTs to confirm. The previous meta-analysis has shown that the treatment options of RCHOP were manifested to prolong OS when given every 14 days instead of 21 days as in case rituximab is omitted (22). In our analysis, it showed that RCHOP-14 and RCHOP-21 have no statistically significant difference in FPS and OS, which is inconsistent with previous findings. Nevertheless, many researchers do not embrace that R-CHOP-14 is the first-line treatment of DLBCL until bringing a randomized study with a control arm of R-CHOP-21 into force, also, the fear that it is too toxic of RCHOP-14 regimen is another reason.

Toxicity was an important endpoint of our study. There is a higher risk of infectious complications associated with RCHOP14, particularly febrile neutropenia, due to infections caused by opportunistic pathogens (23–25). But our study shows that the toxic of R-CHOP-14 regimen is the same as the RCHOP-21 regimen in B-cell patients, rather than exceed. One reason for the RCHOP-14 regimen has the same safety maybe that prophylactic recombinant human granulocyte colony-stimulating factor (G-CSF). G-CSF has often been used to potentiate the antibody-dependent cell-mediated cytotoxicity of rituximab (26, 27), then can be shortened CHOP intervals (7, 8, 28, 29). In spite of prophylactic recombinant human G-CSF, patients were given every 14 days developed more grade 3 to 4 neutropenia than reported previously (14). One of toxic is thrombocytopenia, which more obviously in the RCHOP-14 regimen, and thus may increase the chance of intravenous platelet. Meanwhile, RCHOP-21 is more likely to occur anemia events, which lead to the frequency of transfusion. Another obvious reason is that there is greater heterogeneity between subgroups and the results may be unreliable.

As far as we can see, it is the first meta-analysis to assess the efficacy and toxicity based on rituximab with the CHOP regimen in patients with aggressive or advanced stage indolent B-cell NHL, and it is the first to analyze survival outcomes for patients with different prognostic outcomes based on IPI scores. The data suggested that we would face type 2 errors in the RCTs, the main argument for including OCSs is...
trying to avoid making this mistake. But the meta-analysis is still some limitations. Firstly, two studies maybe cause performance and
detection biases because of they were open-label trails. In the second place, the low number of included studies made it difficult to probe
in-depth with in detail and to interpret potential underlying heterogeneity. When we ascertaining heterogeneity among individual studies for
toxic, which is still significantly high after removing the relevant study. The reason for the high heterogeneity may be the different
prognosis of B-cell NHL and the inconsistent chemotherapy cycle. Therefore, we need more RCT to explore the potential causes of
heterogeneity. In the end, other covariates, such as supportive therapy, preventive measures of toxicity, and the proficiency of the doctor,
could not be balanced in the study.

Conclusions
To sum up, an analysis of data from clinical trials of RCHOP-14 treatment showed that the therapies are safe and effective compare with
the RCHOP-21. However, it was no significant difference in PFS and OS, and that it produces clinical responses similar to those in CR rate.
Additional considerations as regards the choice of followed treatment strategy and balancing treatment-related toxicity may help us to
decide for treatment with RCHOP-14 or RCHOP-21.

Abbreviations
RCHOP: rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone
NHL: Non-Hodgkins Lymphoma
CR: complete response
PFS: progression-free survival
OS: overall survival
AEs: Adverse events
RCTs: randomized controlled trials
OCSs: observational comparative studies
HR: hazard ratio
IPI: international prognostic index
DLBCL: Diffuse large B-cell lymphoma
CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone
RT: radiotherapy
FL: follicular lymphoma
ML: mantle cell lymphoma
NOS: Newcastle-Ottawa-Scale
HRs: hazard ratios
OR: odds ratio
RR: Risk Ratio
NOS: The Newcastle-Ottawa-Scale
G-CSF (Granulocyte Colony Factor)

Declarations
Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

No potential conflicts of interest were disclosed.

Funding

This work was supported by the National Science Foundation of China (NFSC 81460037).

Authors' contributions

Conception and design of the research: YH. Acquisition of data: WqT. Analysis and interpretation of the data: DxJ. Statistical analysis: WL. Obtaining financing: None. Writing of the manuscript: YX. Critical revision of the manuscript for intellectual content: GaC.

Acknowledgements

Not applicable.

References

1. Mugnaini EN and Ghosh N: Lymphoma. Prim Care 43: 661-675, 2016.
2. Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Mauro E, Ferrero S and Ghione P, et al.: Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. Ann Hematol 95: 1107-1114, 2016.
3. Igarashi T, Ogura M, Itoh K, Taniwaki M, Ando K, Kuroda Y, Yamamoto K, Uike N, Tomita A, and Nagai H, et al.: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden. Int J Hematol 104: 700-708, 2016.
4. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, and Yu X, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000.
5. Flowers CR, Sinha R and Vose JM: Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 60: 393-408, 2010.
6. Sinha R, Nastoupil L, and Flowers CR: Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future. Blood Lymphat Cancer 2012: 87-98, 2012.
7. Pfreibundshuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK and Eimermacher H, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104: 634-641, 2004.
8. Pfreibundshuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, and Hasenclever D, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104: 626-633, 2004.
9. Salles G, Barrett M, Foa R, Maurer J, O’Brien S, Valente N, Wenger M, and Maloney DG: Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther 34: 2232-2273, 2017.
10. Ando K: [Follicular lymphoma: recent advances]. Rinsho Ketsueki 59: 2104-2108, 2018.
11. Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA, Takvorian RW, Neuberg D, Hochberg EP, and Abramson JS: Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 55: 538-543, 2014.
12. T E, A P, MA D, A K, NP, C T, C N, S M, N X, and G F: CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group. Cancer journal (Sudbury, Mass.) 13: 327-334, 2007.

13. Higgins JP, Thompson SG, Deeks JJ, and Altman DG: Measuring inconsistency in meta-analyses. BMJ 327: 557-560, 2003.

14. Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, and McMillan A, et al.: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381: 1817-1826, 2013.

15. Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquieres H, Hacini M and Frucht C, et al.: Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14: 525-533, 2013.

16. Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, and Ogura M, et al.: Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol 5: e520-e531, 2018.

17. Payandeh M, Najafi S, Shojaiany FZ and Sadeghi M: Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a report from Iran. Asian Pac J Cancer Prev 17: 1513-1517, 2016.

18. Li X, Huang H, Xu B, Guo H, Lin Y, Ye S, Yi J, Li W, Wu X, and Wang W, et al.: Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Cancer Res Treat 51: 919-932, 2019.

19. Knauf W, Abenhardt W, Mohm J, Rauh J, Harde J, Kaiser-Osterhues A, Janicke M, and Marschner N: Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms. Eur J Haematol 103: 460-471, 2019.

20. Wasterlid T, Hartman L, Szekely E, and Jerkeman M: Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Hematol Oncol 35: 151-157, 2017.

21. Gleeson M, Hawkes EA, Cunningham D, Chadwick N, Counsell N, Lawrie A, Jack A, Smith P, Mouncey P, and Pocock C, et al.: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Br J Haematol 175: 668-672, 2016.

22. Vidal L, Shpilberg O, Gurion R, Monsef I, Raanani P, Ram R, and Gafter-Gvili A: CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma--a meta-analysis of randomized controlled trials. Acta Oncol 55: 77-84, 2016.

23. Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, and Pascutto C, et al.: Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 91: 496-502, 2006.

24. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, and Tam CS: High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, Adriamycin, vincristine, and prednisone. Leuk Lymphoma 51: 797-801, 2010.

25. Tarlov M, McLaughlin P, and Polliack A: A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? Leuk Lymphoma 51: 737-738, 2010.

26. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Ofazlouglu E, Huberman A, Repasky E, and Czuczman MS: Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 9: 5866-5873, 2003.

27. Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouille V, Qvitte P, Klein B, and Rossi JF: Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 26: 2725-2731, 2008.

28. Ohmachi K, Tobinai K, Kobayashi Y, Itoh K, Nakata M, Shibata T, Morishima Y, Ogura M, Suzuki T, and Ueda R, et al.: Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol 22: 1382-1391, 2011.

29. Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, and Mizorogi F, et al.: Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japanese Clinical Oncology Group Study 9505. Ann Oncol 13: 1347-1355, 2002.
| Study            | Location | Disease | Stage   | Median follow-up (months) | Sample size | Number of cycles | Use of G-CSF                                      |
|------------------|----------|---------|---------|--------------------------|-------------|-----------------|-------------------------------------------------|
| Cunningham 2013  | UK       | DLBCL   | I-IV    | 46                       | 540/540     | R/8             | Given to all patients                            |
| Delarue 2013     | France, Belgium, Switzerland, Portugal | DLBCL | II-II   | 56                       | 304/298     | 8/8             | 90% of patients, decision of the treating physician |
|                   |          |                     |         |                          |             |                 | 74% of patients, decision of the treating physician |
| Gleeson 2016     | UK       | DLBCL   | I       | 86.4                     | 22/28       | 6 plus 2 R/8    | Given to all patients                            |
| Payandeh 2016    | Iran     | B-cell NHL | III-IV | 45                       | 66/77       | 6–8/6–8        | Given to all patients                            |
| Watanabe 2018    | Japan    | untreated advanced-stage FL | III-IV | 134.4                    | 151/149     | 6/6             | Given to all patients                            |
| Li 2019          | China    | DLBCL   | I-V     | 45.6                     | 349/353     | 6–8/6–8        | The investigator’s discretion                     |
| Wästerlid 2017   | Swedish  | PMBL    | I-V     | 47.4                     | 1196/910    | 6 / 6          | Not report                                      |
| Knauf 2019*      | German   | DLBCL   | I-V     | 60                       | 264/318     | 6 / 6          | 73% of patients use it at least once              |
|                  |          |                     |         |                          |             |                 | 48.7% of patients use it at least once            |

Note: *: observational comparative studies; R: rituximab; G-CSF: Granulocyte Colony-Stimulating Factor; DLBCL: Diffuse large B-cell lymphoma; PMBL: Primary mediastinal B-cell lymphoma.

| Study        | Wästerlid 2017 | Knauf 2019 |
|--------------|----------------|------------|
| Selection    | *              | *          |
| Selection of the non exposed cohort | * | * |
| Ascertainment of exposure | * | * |
| Demonstration that outcome of interest was not present at start of study | * | * |
| Comparability | Comparability of cohorts on the basis of the design or analysis | ** | ** |
| Outcome      | Assessment of outcome | * | * |
|             | Was follow-up long enough for outcomes to occur | * | * |
|             | Adequacy of follow up of cohorts | * | * |
Table 3
Incidence and relative risk of specific severe adverse events (SAEs) in included trials

| Specific adverse events | Number of studies | RCHOP-14 | RCHOP-21 | Relative risk (95% CI) | P value | P value | I² (%) |
|-------------------------|------------------|----------|----------|------------------------|---------|---------|--------|
| Neutropenia             | 5                | 722/1340 | 896/1408 | 0.93 (0.64–1.36)       | 0.71    | 0.00001 | 98     |
| Thrombocytopenia        | 5                | 102/1340 | 132/1408 | 0.87 (0.60–1.25)       | 0.44    | 0.15    | 41     |
| Anemia                  | 4                | 121/770  | 97/874   | 1.15 (0.88–1.50)       | 0.29    | 0.48    | 0      |
| Febrile neutropenia     | 3                | 103/989  | 134/978  | 0.66 (0.33–1.30)       | 0.23    | 0.001   | 85     |
| Infection               | 4                | 209/1238 | 225/1331 | 1.18 (0.72–1.91)       | 0.51    | 0.0003  | 84     |
| Gastrointestinal toxicity| 4             | 70/1238  | 74/1331  | 1.00 (0.73–1.38)       | 0.98    | 0.52    | 0      |
| Increase in amount of liver enzymes | 3            | 21/521   | 21/521   | 1.04 (0.58–1.86)       | 0.9     | 0.99    | 0      |
| Cardiac-related         | 3                | 15/521   | 14/521   | 1.04 (0.15–7.34)       | 0.97    | 0.02    | 74     |
| Neurological-related    | 3                | 80/989   | 57/978   | 1.41 (0.85–2.33)       | 0.18    | 0.19    | 40     |

Figures

Figure 1
Flow diagram of the study selection process.
Figure 2

A: Risk of bias summary, B: risk of bias graph, C: PFS Funnel plot, D: OS Funnel plot.

| Study or Subgroup | Experimental | Control | Odds Ratio | Odds Ratio |
|-------------------|--------------|---------|------------|------------|
|                   | Events       | Total   | Weight     | M-H Random, 95% CI | M-H Random, 95% CI |
| Cunningham2013[14] | 294          | 313     | 522        | 10.8%       | 0.85 [0.67, 1.11] |
| Delarue2013[15]   | 216          | 200     | 296        | 16.3%       | 0.87 [0.61, 1.24] |
| Gleeson2016[21]   | 21           | 24      | 26         | 1.1%        | 3.50 [0.36, 33.82] |
| Knud2019[9]       | 95           | 122     | 176        | 12.0%       | 0.70 [0.47, 1.07] |
| Li2019[16]        | 241          | 255     | 353        | 17.4%       | 0.66 [0.48, 0.90] |
| Watanabe2018[16]  | 115          | 146     | 164        | 11.2%       | 0.80 [0.51, 1.21] |
| Wåttter2017[20]   | 947          | 680     | 910        | 21.4%       | 1.44 [1.13, 1.80] |
| Total (55%) CI    | 2657         | 2415    | 100.9%     | 0.96 [0.97, 1.23] |
| Total events      | 1919         | 1710    |            |             |

Heterogeneity: Tau² = 0.06, Ch² = 17.09, df = 9 (P = 0.007); I² = 66%
Test for overall effect: Z = 0.30 (P = 0.76)

Figure 3

CR rate for RCHOP-14 VS RCHOP-21.
Figure 4

PFS for RCHOP-14 VS RCHOP-21 of all patients and different IPI scores patient.

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Fixed, 95% CI | Hazard Ratio IV, Fixed, 95% CI |
|-------------------|-------------------|----|--------|--------------------------------|--------------------------------|
| Cunningham2013[14]| -0.04             | 0.07| 5.1    | 1.14 [0.72, 1.77]             | 1.14 [0.72, 1.77]             |
| Li2019[15]        | 0.04              | 0.39| 4.4    | 0.63 [0.39, 0.97]             | 0.63 [0.39, 0.97]             |
| Watanabe2018[16]  | -0.12             | 0.08| 2.0    | 0.79 [0.40, 1.54]             | 0.79 [0.40, 1.54]             |
| Subtotal (95% CI) |                   |    |        | 10.5% [0.71, 1.22]            | 10.5% [0.71, 1.22]            |

Heterogeneity: Chig = 8.72, df = 7 (P = 0.27); I^2 = 20%
Test for overall effect: Z = 1.76 (P = 0.08)

Figure 5

PFS for RCHOP-14 VS RCHOP-21 of all patients and different IPI scores patient.
OS for RCHOP-14 VS RCHOP-21 of all patients and different IPI scores patient.